In addition to new medicines, biotechnology Labs also created millionaires-biotechnology, millionaire-IT information
On June 25, the Wall Street Journal published an article saying, biotechnology laboratories is not only the birth of a new drug, and many scientists and doctors among the ranks of millionaires. 5 years ago, biotech industry malaise, amount of venture capital and IPO numbers hit a record low. Today, the market capitalisation of such companies have been significantly improved, among last year's top 100 companies during the bull market in the industry as a whole sold stock worth as much as $ 8 billion.
The following is the main content of the article:
As with many people who travel often, baoluo·fulideman (Paul a. Friedman) every now and then you fantasize to have a private jet.
Friedman was one of the fortunate could afford to buy private jets. In the past few years, the former associate professor at Harvard Medical School for sale us $ 146.1 million shares of Incyte Corporation. He led the company as CEO through the lean times, eventually successfully launched a drug for cancer treatment.
Despite his enormous wealth, he continued driving his 2009 Audi. "My wife and I live in the original place. "The physician said, now 73. In 2014, he resigned from Incyte CEO positions, but will remain a Director post.
New drugs to extend or improve the lives of millions of people--and still in the development stage, this potential drug--dramatically boosted their shares in biotechnology companies, many scientists, doctors and investors among the ranks of millionaires.
Thanks to the new expensive drugs succeed and investor enthusiasm for riskier companies, biotech leaders joined the United States business winners, hedge funds and technology executive side by side. And some people buy a mansion. Others like Friedman, said compared with the previous day in the lab has not changed a lot.
Biotechnology laboratory drug promotion of the concept of c-type hepatitis, cystic fibrosis and some forms of cancer treatment. Lots of drugs derived from genetic causes and new insights into the biological process of the disease, thanks to years of Government and private sector study.
Great shift
Based on public documents, the Wall Street Journal analysis found that last year, the top 100 biotechnology companies during the bull market in the industry as a whole sold stock worth $ 8 billion.
The figure set a new record in the industry, also marked its transformation. 5 years ago, the industry's malaise, venture capital and the IPO (initial public offer) number of all-time. During the 2004 to 2011, the biotechnology company directors and executives sold shares worth $ 1.2 billion on average each year, and by 2012 to 2014, that figure rose to 2.3 billion dollars, almost doubling the 1 time.
P according to Dow, biotechnology company p composite 1500 index annual average total market value from $ 180 billion in 2010, an increase of twice more than doubled to $ 594.2 billion this year.
United States interest rates attracted investors to higher-risk, higher-return investments, benefited from the biotechnology industry. Health care law brings help to the industry: the insured person increased by millions of people access to prescription drug coverage for the first time, the potential customer base of the company has been expanding.
Drug prices are reviewed, concerns about government price controls rise, leading biotech stocks has plunged recently, NASDAQ Biotechnology stocks since January by 26%. Leerink Partners senior biotechnology analyst jiefuli·bogesi (Geoffrey c. Porges) says, "each a small company, every concept, are attracted to the Fund. Therefore, we may have to provide the industry with too much money. ”
Most new drugs have few competitive products protected by a patent, or the price limits, such a "price cap" expectations that biotechnology companies with approved drugs (as well as those who only give the kind of commitment the company) sought after by investors.
Last year, losses from biotechnology company executives and directors sold shares worth $ 2.67 billion, one-third of all companies in the industry. Investors of a potential large shares of the biotechnology company's desire to sharply pushed up the shares of companies in the sector.
Mergers and acquisitions bring wealth
The year 2015 is the record number of deals. Some people who once belonged to shareholders to buy biotechnology companies, where the first Pharmacyclics CEO Robert Duggan (Robert w. Duggan), top of the list: the company was bought by AbbVie for $ 21 billion, with 3.46 billion dollars in cash and shares.
In 2004, shares of the loss before the biotechnology company, had not been involved in the drug development industry. 4 years later, he used his 29% per cent control of the company. Then, in September 2008, Pharmacyclics has a market value of $ 53 million since 1991, recorded a loss of $ 340 million.
In 2013, Pharmacyclics first drug Imbruvica received United States food and Drug Administration approval. After that, Imbruvica became a popular drug to treat the most common type of adult leukemia. Studies have found that compared to older drugs, it can slow disease progression, and has less side effects.
Use Imbruvica in the treatment of the patient needs to spend about $ 100,000 a year, 2014 years of global sales of the drug reached $ 548 million, and last year the number climbed to more than $ 1 billion.
"It shows that if you picked the right objects, offers a modest investment, you can generate a lot of money in return. "When to Pharmacyclics said the injection of approximately $ 50 million. Other executives and directors of the company amounted to a profit of $ 419 million from the deal.
Receptos company Celgene to prices of $ 7.2 billion last year when the back door, it's 14 top executives and directors with stock ownership amounted to us $ 540.5 million. Receptos precursor drugs has not been completing late-stage study.
Receptos, former Chief Medical Officer xiela·gujilate (Sheila Gujrathi) earn about $ 75 million when the transaction is completed. Among the big winners in the biotech industry last year, she was one of a handful of women.
"After you set foot in the pharmaceutical industry, you don't think you might in the future become a multimillionaire. "She said," and when they find themselves when there is a lot of wealth, will feel very surprised that changed his life. ”
Among the companies that remain, the executives and directors of Gilead Sciences shares last year, worth US $ 413.5 million for all biotech companies the most. With launch of two best-selling drugs for hepatitis c, including the Harvoni, the company's share price has soared in recent years. Harvoni last year in the United States and generated sales of $ 10.1 billion.
Gilead, the pricing (per course of treatment ranging from $ 84,000 to $ 94,500) criticism from health insurance companies and Government officials. Insurers refusing for the most serious patients with insurance to provide such drugs to people outside. Congressional investigations last year claimed that Gilead intends to set those prices, those drugs are almost always are not within the scope of coverage.
Gilead spokesman said, "we support our treatment methods of pricing mechanisms, since they can bring benefits to patients, they also have great value. ”
Years of losses
Biotechnology is different from the software and other technology products in the category of, because the development of new medicines, study its efficacy, often requires hundreds of millions of dollars and more than a decade of time. By contrast, Smartphone app development costs are much lower, anyone with programming skills who can develop and sell.
Even though research and development for many years, potential drugs in late-stage studies may have failed. Many biotechnology companies are expected to continue next loss.
"The industry norm is, struggling to prove their profits, trying to convince people you're doing is not only risky scientific experiments. "After graduation from medical school into drugs Borges said.
Regeneron Pharmaceuticals was founded in 1988 in New York tar village in November 2011, its drug to treat age-related vision loss before Eylea approved by the FDA, it accumulated a loss of 1.27 billion dollars. Treatment with Eylea, costs $ 11,000 to $ 16,000 a year. Last year, Eylea in the United States market and generated sales of $ 2.68 billion.
The company's shares during the period from 2011 to 2015 has increased 16 times, as the best performing standard and poor's 500 index companies.
Regeneron's Chief Scientific Officer, United inventors of Eylea qiaozhi·yakeboluosi (George d. Yancopoulos) through the sale of shares of the company last year received $ 48.6 million; the company's executives and directors through a sale in the amount of $ 226.6 million.
Regeneron CEO laiangnade·shilaifuer (Leonard Schleifer) during the 2012 to 2014 period amounts to $ 136.5 million shares sold.
NASDAQ 100 index (NASDAQ stock market tracked index of largest non-financial companies) amount of shares the company among the top 20 biotechnology company executives and directors hold seven seats. Among them, the Gilead Sciences Executive Chairman John Martin (John c. Martin) ranked sixth, although he sold $ 190.6 million shares, compared to the top three selling shares worth mentioning--Microsoft's Bill Gates (Bill Gates) and two co-founders Larry page of Google (Larry Page) and Sergey Brin (Sergey Brin), three shares were sold last year for more than $ 1 billion.
Leader Gilead Sciences AIDS virus (HIV), hepatitis b and hepatitis c after the research and development of new drugs, is itself organic chemist Martin in March this year, resigned from the company's CEO position. According to the company spokesman, said Martin during his term to change the three kinds of treatments for infectious diseases.
The company's profit of $ 18.12 billion last year, according to the poor's global market intelligence data, which ranked fifth in the poor's 500 blue-chip stocks after Apple, JPMorgan Chase, Berkshire Hathaway (Berkshire Hathaway) and Wells Fargo.
Gilead net profits of 55 cents per $ 1 of revenue, profit margins on the p 500 companies ranked in second place.
Martin has sold $ 661.9 million shares of Gilead from 2011 to 2015. He still owns about 4 million shares of the company's shares, worth about $ 330 million.
Gilead, former Senior Vice President Bruce Montgomery (Bruce Montgomery), Gilead is famous for frugal spending. He said, the company's line of credit limited, Executive "better have a very good reason" to use the company's business, rather than on a commercial flight.
"If you met these people at Home Depot, they looked like ordinary people, you do not know that they were rich. "He said.
Returns:
Has a doctorate in biochemistry biotechnology investor luode·fugesen (Rod Ferguson) to see the rise of this industry for the past 30 years, with the ups and downs of investor sentiment for the period.
He said that in 2012, biotechnology is not popular, even with a late development stage, future products, the company would be difficult to complete the financing. The Halloween of that year, Auspex Pharmaceuticals of Ferguson's venture capital company a stake in the private company, the valuation of the latter only "poor" $ 26.2 million.
In February 2014, Auspex completed IPO, valued at about $ 270 million. By December, the company announced late stage studies showed its new drug improves the symptoms of Huntington's disease.
The company's market value has doubled overnight 1 time, to $ 1.39 billion.
Sir Alex Ferguson believes that the year 2015 is the biotechnology boom peaked. "I'm at the biotechnology industry have been around for a long time--when enthusiasm is very high, it is time for you to quit. ”
Last year, Auspex was bought by Teva Pharmaceutical Industries for $ 3.5 billion the next. Alex VC firms received $ 252.6 million from the deal, achieving almost 18 times the return on investment. "Deny the lucky man is either a fool or a liar. This time we are lucky. ”
In May, Teva said the FDA rejected approval of new drugs Auspex, request further laboratory data. The company said it is negotiate with the FDA, "as soon as possible" was approved.
除了新药品，生物技术实验室还催生百万富翁 - 生物技术,百万富翁 - IT资讯
6月25日消息，华尔街日报发表文章称，生物技术实验室不仅仅诞生新药品，还让不少科学家和医生跻身百万富翁之列。5年前，生物技术行业还萎靡不振，风险投资额和IPO数量创下历史新低。如今，该类公司的市值则有了显著的提升，去年当中最大的100家公司在行业牛市期间合计售出的股票价值高达80亿美元。
以下是文章主要内容：
跟很多时常出行的人一样，保罗·弗里德曼（Paul A. Friedman）时不时就会幻想拥有一家私人飞机。
弗里德曼是买得起私人飞机的幸运者之一。在过去的几年里，该前哈佛医学院副教授出售了价值1.461亿美元的Incyte公司股票。他作为CEO带领该公司度过了拮据时期，最终成功推出一种治疗癌症的药物。
尽管拥有巨额财富，他仍继续开他的那辆2009款奥迪。“我和妻子还居住在原来的地方。”该现年73岁的医师说道。他于2014年辞去Incyte CEO职务，但仍担任董事一职。
延长或者改善无数人的生活的新药物——以及仍处于研发阶段的、有这一潜力的药物——显著提振了拥有它们的生物技术公司的股价，让许多科学家、医生及投资者跻身百万富翁之列。
得益于新高价药物带来的成功和投资者对高风险行业公司的热情，生物技术领导者们加入了美国企业界赢家行列，并肩对冲基金和科技高管。当中，有的人买了豪宅。也有像弗里德曼这样的称生活相比以前在实验室的日子并没很大变化。
生物技术实验室构想的药物促进了C型肝炎、囊肿性纤维化及部分癌症的治疗。很多药物产生于基因成因和疾病生物过程方面的新见解，得益于多年以来政府和私有机构的研究。
巨大转变
华尔街日报基于企业公开文件的分析发现，去年，最大的100家生物技术公司在该行业的牛市期间合计售出的股票价值80亿美元。
该数字刷新了该行业的记录，也标志着它的巨大转变。5年前，该行业还萎靡不振，风险投资额和IPO（首次公开招股）数量均创下历史新低。2004年到2011年期间，生物技术公司的董事和高管每年售出的股份平均价值12亿美元，而到2012年至2014年，这一数字增长到了23亿美元，几乎翻了一倍。
标普道琼斯指数公司的数据显示，标普综合1500指数的生物技术公司年度平均合计市值已从2010年的1800亿美元，增长两倍多至今年的5942亿美元。
美国的低利率吸引投资者去进行更高风险、回报更高的投资，生物技术行业因而受益。医疗保健法律也给该行业带来了帮助：使得参加保险的人增加了数百万，很多人首次获得处方药费保险，该类公司的潜在顾客群因而得到扩大。
药品价格被审查，有关政府实施价格管制的担忧抬头，致使生物技术类股票近期出现大跌，纳斯达克生物技术板块1月以来累计下跌26%。Leerink Partners高级生物技术分析师杰弗里·伯格斯（Geoffrey C. Porges）说道，“每一家小公司，每一个概念，都吸引到了资金。因此，我们也许给该行业提供过多的资金了。”
大多数有专利保护的新药物都鲜有竞争产品，也缺少价格限制，这样一种“价格无上限”的预期令拥有获批核药品的生物技术公司（以及那些仅给予该类承诺的公司）持续受到投资者的追捧。
去年，来自亏损生物技术公司的高管和董事的售股总值26.7亿美元，在该行业所有公司中占三分之一。投资者对下一潜在的大型生物技术公司股份的渴望，大幅推高了该行业的公司股价。
并购带来财富
2015年是并购交易数量创纪录的一年。部分大发横财的人属于被收购生物技术公司的股东，其中前Pharmacyclics CEO罗伯特·达根（Robert W. Duggan）位居榜首：在该公司被AbbVie以210亿美元买下时，获得34.6亿美元的现金和股份。
在2004年入股该处于亏损的生物技术公司之前，达根未曾涉足过药品开发行业。4年后，他利用其29%持股控股该公司。当时，2008年9月，Pharmacyclics的市值为5300万美元，自1991年以来录得亏损3.4亿美元。
2013年，Pharmacyclics的第一款药物Imbruvica获得美国食品和药品管理局的批准。在那之后，Imbruvica成为了治疗最常见的成人白血病类型的热门药物。研究发现，相比旧式药物，它能够减缓病情发展，且副作用较少。
使用Imbruvica治疗的病人每年需要花费10万美元左右，该药物2014年的全球销售额达到5.48亿美元，去年该数字攀升至超过10亿美元。
“它表明，如果你选对了对象，提供适度的投资，你是能够获得不菲的回报的。”当初向Pharmacyclics注资大约5000万美元的达根说道。其他的公司高管和董事从该交易中共计获利4.19亿美元。
Receptos公司去年被Celgene以72亿美元的价格收归门下时，它的14位高管和董事凭借持股共计获得5.405亿美元。Receptos的先导药物还没有完成后期阶段的研究。
Receptos前首席医疗官谢拉·古吉拉特（Sheila Gujrathi）在该交易完成时进账7500万美元。在去年生物技术行业的大赢家当中，她是少数的几位女性之一。
“在你涉足医药行业后，你不会想到你将来可能会成为千万富翁。”她说道，“而当发现自己有了大量财富时，会感觉很惊讶，那也改变了自己的生活。”
在仍然存在的公司当中，Gilead Sciences的高管和董事去年的售股价值达4.135亿美元，为所有的生物技术公司之最。随着两款热销的C型肝炎药物的推出，其中包括Harvoni，该公司的股价近年来大幅飙涨。Harvoni去年在美国的销售额达到101亿美元。
Gilead还因定价问题（每疗程8.4万美元到9.45万美元不等）招致医疗保险公司和政府官员的诟病。部分保险公司拒绝对最严重病患以外的人提供这类药品的保险。国会去年的调查声称，Gilead有意设定那些价格使得那些药品几乎都不在保险覆盖范围之内。
Gilead发言人表示，“我们支持我们的治疗方法的定价机制，因为它们能够给病患带来益处，它们也拥有巨大的价值。”
连年亏损
生物技术有别于软件以及其它范畴的科技产品，因为开发新药物，研究它是否具有疗效，往往需要耗费数亿美元和十年以上的时间。相比之下，智能手机应用的开发成本要低得多，任何拥有编程能力的人都可以去开发和出售。
即使研发了多年时间，富有潜力的药品在后期研究阶段也有可能会遭遇失败。很多生物技术公司都预期接下来将会连年亏损。
“该行业的常态是，苦苦证明自己有盈利，极力说服人们自己在做的不只是高风险的科学实验。”从医学院毕业后进入药品行业的伯格斯说道。
位于纽约州柏油村的Regeneron Pharmaceuticals创立于1988年，在2011年11月其治疗年龄相关视力丧失的药品Eylea获得FDA批准之前，它累计亏损12.7亿美元。使用Eylea治疗，每年需要花费1.1万美元至1.6万美元。去年，Eylea在美国市场的销售额达到26.8亿美元。
该公司的股价在2011年至2015年期间增长了16倍，为该时期表现最好的标准普尔500指数公司。
Regeneron的首席科学官、Eylea联合发明者乔治·雅克波罗斯（George D. Yancopoulos）去年通过出售公司股份获得4860万美元；该公司的高管和董事通过售股共计获得2.266亿美元。
Regeneron CEO莱昂纳德·施莱弗尔（Leonard Schleifer）在2012年至2014年期间共计售出1.365亿美元的股票。
在纳斯达克100指数（纳斯达克股票市场追踪最大的非金融类公司的指数）公司售股金额最高的20个人中，生物技术公司的高管和董事占七席。其中，Gilead Sciences执行董事长约翰·马丁（John C. Martin）排名第六，尽管他卖出的1.906亿美元股票，相比排名前三的售股者不值一提——微软的比尔·盖茨（Bill Gates），谷歌的两位联合创始人拉里·佩奇（Larry Page）和谢尔盖·布林（Sergey Brin），三人去年售出的股份均超过10亿美元。
在领导Gilead Sciences为艾滋病病毒（HIV）、乙型肝炎和丙型肝炎研发新药物之后，本身是有机化学家的马丁于今年3月辞去公司CEO职务。据该公司的发言人称，马丁在任期内改变了那三种传染性疾病的治疗。
该公司去年实现盈利181.2亿美元，根据标普全球市场情报数据，该表现在标普500蓝筹股中位居第五，仅次于苹果、摩根大通、伯克希尔哈撒韦（Berkshire Hathaway）和富国银行。
Gilead每1美元收入的净利润达55美分，利润率在标普500指数公司中排名第二位。
马丁在2011年至2015年卖出了6.619亿美元的Gilead股份。他目前仍持有大约400万股公司股份，总值约3.3亿美元。
Gilead前高级副总裁布鲁斯·蒙哥马利（Bruce Montgomery）表示，Gilead以节俭开支而著称。他说，该公司的信用卡额度有限，高管“最好要有很好的理由”才能使用公司的商务机，而非乘坐商业航班。
“如果你在家得宝碰见这些人，他们看上去就像平常人，你根本不会知道他们很有钱。”他说道。
巨额回报
拥有生物化学博士学位的生物技术投资者罗德·弗格森（Rod Ferguson）亲身目睹了该行业过去三十年的兴衰起伏，期间伴随着投资者情绪的大起大落。
他说，2012年，生物技术不受青睐，即便拥有处于后期开发阶段的、有前景的产品，公司也难以完成融资。那一年的万圣节，弗格森旗下的风险投资公司入股私有公司Auspex Pharmaceuticals，当时后者的估值只有“可怜的”2620万美元。
2014年2月，Auspex完成IPO，估值约为2.7亿美元。到12月，该公司宣布，后期阶段研究显示，其新药物改善了亨廷顿氏病的症状。
该公司的市值一夜之间翻了一倍，达到13.9亿美元。
弗格森认为，2015年是生物技术繁荣达到峰值的一年。“我身处生物技术行业已经有很长一段时间了——当投资热情十分高涨时，你是时候退出了。”
去年，Auspex被Teva Pharmaceutical Industries以35亿美元的高价买下。弗格森的风投公司从该笔交易获得2.526亿美元，实现几乎18倍的投资回报率。“否认走运的人要么是傻瓜，要么是骗子。这一次我们走大运了。”
5月，Teva称，FDA拒绝批准Auspex的新药物，要求提供更多的实验室数据。该公司称，它正在跟FDA磋商，以“尽快”获得批准。